CellaVision AB (STO:CEVI) presented its Q1 2025 results on April 29, showcasing strong performance across all regions despite a challenging market environment. The company’s stock has responded ...
Quarterly Performance Highlights CellaVision reported net sales of SEK 191 million for Q2 2025, representing a modest 1.9% increase from SEK 188 million in the same period last year. While organic ...
HORIBA UK Ltd, Medical has introduced a new automated digital cell morphology solution in collaboration with CellaVision to help hematology laboratories simplify and expedite the performance of blood ...
CellaVision AB (STO:CEVI) presented its Q1 2025 results on April 29, showcasing strong performance across all regions despite a challenging market environment. The company’s stock has responded ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback